Medivir: Additional Orphan Designation for MIV-711 - Redeye
Redeye comments on the new orphan drug designation for the treatment of Osteogenesis Imperfecta from the FDA. It could bolster the attractiveness of MIV-711 for partners.
ANNONS
Redeye comments on the new orphan drug designation for the treatment of Osteogenesis Imperfecta from the FDA. It could bolster the attractiveness of MIV-711 for partners.
